Sandoz Gains Regulatory Approval for Generic Semaglutide in Canada

Sandoz has received marketing authorization from Health Canada for Sandoz® Semaglutide, a generic version of Ozempic®, marking a step forward in expanding affordable diabetes treatment options. This approval supports the Canadian healthcare system, building on Sandoz's recent achievements, including tirzepatide FDA application acceptance in the US and semaglutide approval in Brazil.

The approval is crucial as nearly six million Canadians live with diabetes, with type 2 making up 90-95% of cases. Sandoz aims to make semaglutide accessible to more patients, with predictions that diabetes prevalence will rise to 7.3 million by 2034. The Canadian GLP-1 market is valued at USD 2.6 billion, highlighting the demand for treatments like semaglutide.

Sandoz CEO Richard Saynor emphasizes the global demand for GLP-1s and the company's focus on providing affordable options that enhance healthcare sustainability. The approval aligns with Sandoz's strategy to expand access to essential medicines. However, this development will not affect Sandoz's financial guidance for 2026.